#USA #Los Angeles #Nordic Pharma #LACRIFILL #Dry Eyes

Nordic Pharma Presents LACRIFILL® Canalicular Gel Insights

Nordic Pharma, Inc., a subsidiary of the Nordic Group B.V., recently unveiled pivotal patient data and experience studies regarding its innovative therapeutic solution, LACRIFILL® Canalicular Gel, at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Los Angeles, California, from April 25-28, 2025. This event marks a significant opportunity for healthcare professionals to understand the advancements in treating dry eye syndrome with cutting-edge solutions.

Key Findings on LACRIFILL® Canalicular Gel

The April issue of Cataract Refractive Surgery Today (CRST) featured a case study titled "Improved Visual Outcomes With LACRIFILL® Canalicular Gel-Assisted Ocular Surface Optimization," authored by Drs. Neel Desai and Subhashini Chandrasekaran. This study illustrates how the utilization of LACRIFILL Canalicular Gel can notably enhance visual acuity and optical quality, especially in patients struggling with fluctuating vision post-cataract surgery.

Additionally, the forthcoming May issue of CRST will include results from a patient experience survey involving first-time and repeat users of LACRIFILL Canalicular Gel. Remarkably, 98.11% of respondents indicated they would choose to use LACRIFILL Canalicular Gel again, showcasing the product’s acceptance and effectiveness in treating symptoms of dry eye.

A Voice from the Industry

Dr. Jai Parekh, Chief Commercial Officer of Eye Care U.S., commented, “A year after launching at ASCRS 2024, we have compelling case studies and patient experience data from both physicians and patients that demonstrate how LACRIFILL Canalicular Gel transforms practices and enhances patient lives. It is exhilarating to share proven results with this year’s attendees focusing on innovative patient care.”

Dr. Priya Mathews from Center for Sight also expressed her enthusiasm, stating, “I’m eager to share my experiences and the tangible benefits of LACRIFILL Canalicular Gel with those attending.” This collective effort underlines the commitment that Nordic Pharma has towards improving patient outcomes in eye care through innovative solutions.

Engage with Nordic Pharma

Attendees of the ASCRS Annual Meeting are encouraged to visit the Nordic Pharma booth (#717), where they can engage directly with professionals and gain insights into the remarkable contributions of LACRIFILL Canalicular Gel. In addition, Nordic Pharma will honor firefighters' heroic efforts amid California’s recent wildfires by providing a QR code for donations to the Los Angeles Fire Department Foundation. By doing so, Nordic Pharma aims to double the impact of donations, showcasing their dedication to community support alongside their commitment to eye health.

To learn more about LACRIFILL Canalicular Gel and ordering options, interested parties can visit lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is a privately-owned, medium-sized international pharmaceutical company focused on developing and marketing specialty products. Its portfolio expansion has been driven by targeted development and strategic acquisitions in areas such as ophthalmology, rheumatology, and women’s health. With deep-rooted operations across Europe, the Nordic Group has expanded its global footprint through recent acquisitions.

As part of SEVER Life Sciences, established in 2019, Nordic Group B.V. integrates three complementary companies that offer a diverse range of products, pharmaceutical development services, and delivery technologies, enhancing the overall impact on patient care.

About Nordic Pharma, Inc.

Nordic Pharma, Inc. collaborates with established global biopharmaceutical companies, uniquely positioning itself to leverage expertise in launching biotechnologically produced medicines and sophisticated technologies. Through such collaborations, Nordic Pharma continues to contribute significantly to advancements in the pharmaceutical landscape.

Conclusion

In conclusion, the presentation of LACRIFILL Canalicular Gel exemplifies Nordic Pharma’s dedication to pioneering solutions for dry eyes and its responsibility towards community welfare. The insights shared at the ASCRS Annual Meeting highlight the potential transformative effects of this innovative therapy on patient experiences and outcomes.